GlassScriptPhysician profile
Stacey Lynn Bates
NPI 1962900431
$1,576.20
in general payments reported to CMS, 2019-2025
21 companies · $628 in 2025
The $628 reported for 2025 was more than what 80% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $80.00 · 2023: $282 · 2024: $344 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $355.50 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Glaxosmithkline, LLC. | $272.78 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $141.04 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $94.75 | 2023-2024 | Dupixent |
| United Therapeutics Corporation | $80.00 | 2022 | |
| Grifols USA, LLC | $73.87 | 2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $56.93 | 2025 | Zerbaxa |
| Takeda Pharmaceuticals U.S.A., INC. | $55.13 | 2023 | Glassia |
| Abbvie INC. | $54.42 | 2025 | |
| Harmony Biosciences LLC | $33.25 | 2023 | Wakix |
| Mallinckrodt Hospital Products INC. | $32.70 | 2023-2024 | Acthar |
| Genzyme Corporation | $29.35 | 2024-2025 | |
| Pulmonx Corporation | $29.32 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Alk-Abello, INC | $23.62 | 2024 | Ragwitek, Odactra, Grastek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.36 | 2023 | Imfinzi |
| Avadel Cns Pharmaceuticals, LLC | $21.85 | 2024 | Lumryz |
| Zoll Respicardia, INC. | $21.14 | 2025 | Remede System |
| Amgen INC. | $19.91 | 2023 | Tezspire |
| Verona Pharma, INC. | $19.37 | 2025 | Ohtuvayre |
| 3b Medical, INC. | $13.92 | 2024 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.